The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
29 Nov

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model. 177Lu-PNT6555, the lead of the PNT2004 pan-cancer fibroblast activation protein-α (FAP-α) targeted program, is currently in a phase 1 trial.

Press Release
14 Nov

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003.